Lantern Pharma Inc.(LTRN)Earnings, Financials & Key Ratios
LTRN•NASDAQ
$2.04
$23M mkt cap·Price updated May 7, 2026
AboutLantern Pharma Inc., a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. Its advanced drug candidate is LP-100, which is in phase II clinical trials to treat metastatic, castration-resistant, and prostate cancer. The company also develops LP-300 as a combination therapy for non or never-smokers with non-small cell lung cancer adenocarcinoma. In addition, its preclinical development drug candidate is LP-184, an alkylating agent that damages DNA in cancer cells that overexpress certain biomarkers or that harbor mutations in DNA repair pathways. Further, the company operates ADC program, an antibody drug conjugate therapeutic approach for cancer treatment. Additionally, the company's artificial intelligence platform RADR uses big data analytics and machine learning for combining molecular data. The company was incorporated in 2013 and is headquartered in Dallas, Texas.Show more
- Revenue$0
- EBITDA-$22M-25.4%
- Net Income-$21M-30.2%
- EPS (Diluted)-1930.92-131255.1%
- ROE-66.93%-103.3%
- ROIC-100.6%-42.9%
- Debt/Equity0.01+100.6%
LTRN Key Insights
Lantern Pharma Inc. (LTRN) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓Trading at only 1.0x book value
✗Weaknesses
- ✗Weak Piotroski F-Score: 2/9
- ✗Weak momentum: RS Rating 8 (bottom 8%)
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
LTRN Price & Volume
Lantern Pharma Inc. (LTRN) stock price & volume — 10-year historical chart
Loading chart...
LTRN Growth Metrics
Lantern Pharma Inc. (LTRN) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM0.9%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM1.69%
Return on Capital
10 Years-145.06%
5 Years-43.08%
3 Years-43.63%
Last Year-71.42%
LTRN Peer Comparison
Lantern Pharma Inc. (LTRN) competitors in Oncology Therapeutics Developers — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 ONCO | 1.38M | 0.40 | -0.09 | -67.7% | -17.21% | -189.85% | 0.00 | |
 CASI | 2.33M | 0.15 | -0.06 | -15.77% | -183.93% | -301.8% | 11.96 | |
 ALDX | 104.08M | 1.73 | -1.84 | -87.71% | 0.22 | |||
 IMVT | 5.53B | 27.22 | -9.97 | -47.07% | 0.00 | |||
 RXRX | 1.46B | 3.27 | -2.27 | 26.92% | -8.44% | -54.32% | 0.07 | |
 SDGR | 992.29M | 13.28 | -9.42 | 23.29% | -40.6% | -30.85% | 0.30 | |
 ABSI | 893.82M | 5.75 | -6.85 | -38.24% | -73.06% | -63.58% | 0.03 | |
 INVA | 1.93B | 22.80 | 6.91 | 18.52% | 118.91% | 46.47% | 0.23 |
Compare LTRN vs Peers
Lantern Pharma Inc. (LTRN) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
LTRN Income Statement
Lantern Pharma Inc. (LTRN) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Revenue Growth % | - | - | - | - | - | - | - | - |
| Cost of Goods Sold | -2.54K | 1.63K | 0 | 0 | 0 | 174.84K | 0 | 55.33K |
| COGS % of Revenue | - | - | - | - | - | - | - | - |
| Gross Profit | 2.54K▲ 0% | -1.63K▼ 164.0% | 0▲ 100.0% | 0▲ 0% | 0▲ 0% | -174.84K▲ 0% | 0▲ 100.0% | -55.33K▲ 0% |
| Gross Margin % | - | - | - | - | - | - | - | - |
| Gross Profit Growth % | - | -163.95% | 100% | - | - | - | 100% | - |
| Operating Expenses | 1.73M | 2.43M | 5.91M | 12.59M | 14.43M | 17.7M | 22.22M | 19.62M |
| OpEx % of Revenue | - | - | - | - | - | - | - | - |
| Selling, General & Admin | 1.15M | 1.48M | 3.66M | 5.02M | 5.83M | 5.98M | 6.09M | 6.58M |
| SG&A % of Revenue | - | - | - | - | - | - | - | - |
| Research & Development | 572.1K | 953.18K | 2.24M | 7.57M | 8.6M | 11.89M | 16.13M | 13.04M |
| R&D % of Revenue | - | - | - | - | - | - | - | - |
| Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | -174.84K | 0 | 0 |
| Operating Income | -1.73M▲ 0% | -2.43M▼ 40.6% | -5.91M▼ 143.3% | -12.59M▼ 113.1% | -14.43M▼ 14.6% | -17.88M▼ 23.9% | -22.22M▼ 24.3% | -19.67M▲ 0% |
| Operating Margin % | - | - | - | - | - | - | - | - |
| Operating Income Growth % | - | -40.65% | -143.32% | -113.12% | -14.62% | -23.87% | -24.27% | - |
| EBITDA | -1.73M | -2.43M | -5.9M | -12.58M | -14.42M | -17.7M | -22.2M | -19.61M |
| EBITDA Margin % | - | - | - | - | - | - | - | - |
| EBITDA Growth % | - | -40.35% | -143.34% | -113.13% | -14.6% | -22.74% | -25.4% | 7.25% |
| D&A (Non-Cash Add-back) | -2.54K | 1.63K | 3.39K | 6.76K | 10.08K | 174.84K | 17.28K | 64.4K |
| EBIT | -1.73M | -2.43M | -5.91M | -12.59M | -14.43M | -15.96M | -22.22M | -19.48M |
| Net Interest Income | 0 | 0 | 0 | 67.93K | 0 | 765.39K | 742.36K | 526.85K |
| Interest Income | 0 | 0 | 0 | 67.93K | 204.35K | 765.39K | 742.36K | 526.85K |
| Interest Expense | 0 | 0 | 0 | 0 | 204.35K | 0 | 0 | 0 |
| Other Income/Expense | 0 | 0 | 0 | 228.48K | 172.81K | 1.92M | 1.44M | 751.71K |
| Pretax Income | -1.73M▲ 0% | -2.43M▼ 40.6% | -5.91M▼ 143.3% | -12.36M▼ 109.3% | -14.26M▼ 15.3% | -15.96M▼ 11.9% | -20.78M▼ 30.2% | -18.92M▲ 0% |
| Pretax Margin % | - | - | - | - | - | - | - | - |
| Income Tax | 2.54K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | -0.15% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Income | -1.73M▲ 0% | -2.43M▼ 40.6% | -5.91M▼ 143.3% | -12.36M▼ 109.3% | -14.26M▼ 15.3% | -15.96M▼ 11.9% | -20.78M▼ 30.2% | -18.92M▲ 0% |
| Net Margin % | - | - | - | - | - | - | - | - |
| Net Income Growth % | - | -40.65% | -143.32% | -109.25% | -15.34% | -11.93% | -30.2% | 0.9% |
| Net Income (Continuing) | -1.73M | -2.43M | -5.91M | -12.36M | -14.26M | -15.96M | -20.78M | -18.92M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.28▲ 0% | -0.39▼ 39.3% | -0.95▼ 143.6% | -1.13▼ 18.9% | -1.31▼ 15.9% | -1.47▼ 12.2% | -1930.92▼ 131255.1% | -1.75▲ 0% |
| EPS Growth % | - | -39.29% | -143.59% | -18.95% | -15.93% | -12.21% | -131255.1% | 1.69% |
| EPS (Basic) | -0.28 | -0.39 | -0.95 | -1.13 | -1.31 | -1.47 | -1930.92 | - |
| Diluted Shares Outstanding | 6.22M | 6.27M | 6.22M | 10.9M | 10.85M | 10.84M | 10.76M | 10.83M |
| Basic Shares Outstanding | 6.22M | 6.27M | 6.22M | 10.9M | 10.85M | 10.84M | 10.76M | 10.83M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - |
LTRN Balance Sheet
Lantern Pharma Inc. (LTRN) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 445.16K | 1.23M | 20.24M | 72.72M | 58.72M | 43.34M | 25.25M | 13.46M |
| Cash & Short-Term Investments | 445.16K | 1.23M | 19.23M | 70.73M | 55.2M | 41.3M | 24.01M | 12.36M |
| Cash Only | 445.16K | 1.23M | 19.23M | 51.52M | 37.2M | 21.94M | 7.51M | 8.39M |
| Short-Term Investments | 0 | 0 | 0 | 19.2M | 17.99M | 19.36M | 16.5M | 3.97M |
| Accounts Receivable | 0 | 0 | 0 | 181K | 0 | 860K | 0 | 0 |
| Days Sales Outstanding | - | - | - | - | - | - | - | - |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - | - |
| Other Current Assets | 0 | 0 | 0 | 378.95K | 541.18K | 745.65K | 1.23M | 1.1M |
| Total Non-Current Assets | 4.67K | 199.76K | 122.71K | 1.23M | 113.58K | 306.29K | 324.16K | 165.81K |
| Property, Plant & Equipment | 4.67K | 8.76K | 21.51K | 216.19K | 95.69K | 280.42K | 287.43K | 129.07K |
| Fixed Asset Turnover | - | - | - | - | - | - | - | 0.00x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 0 | 0 | 1M | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 0 | 191K | 101.2K | 17.89K | 17.89K | 25.87K | 36.74K | 146.95K |
| Total Assets | 449.83K▲ 0% | 1.43M▲ 218.5% | 20.36M▲ 1321.2% | 73.95M▲ 263.2% | 58.84M▼ 20.4% | 43.65M▼ 25.8% | 25.57M▼ 41.4% | 13.63M▲ 0% |
| Asset Turnover | - | - | - | - | - | - | - | 0.00x |
| Asset Growth % | - | 218.47% | 1321.19% | 263.22% | -20.44% | -25.82% | -41.41% | -194.39% |
| Total Current Liabilities | 651.63K | 489.29K | 552.34K | 2.33M | 2.8M | 2.68M | 4.33M | 4.04M |
| Accounts Payable | 97.63K | 478.29K | 432.34K | 2.17M | 0 | 942.21K | 0 | 3.95M |
| Days Payables Outstanding | -14.01K | 107.3K | - | - | - | 1.97K | - | 21.15K |
| Short-Term Debt | 0 | 0 | 0 | 152.06K | 0 | 0 | 0 | 93.95K |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 535K | 2K | 120K | 0 | 2.75M | 1.56M | 4.14M | 0 |
| Current Ratio | 0.68x | 2.52x | 36.64x | 31.26x | 20.99x | 16.18x | 5.83x | 5.83x |
| Quick Ratio | 0.68x | 2.52x | 36.64x | 31.26x | 20.99x | 16.18x | 5.83x | 5.83x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 0 | 0 | 108.5K | 52.89K | 0 | 61.5K | 52.84K | 0 |
| Long-Term Debt | 0 | 0 | 108.5K | 0 | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 0 | 0 | 0 | 52.89K | 0 | 61.5K | 52.84K | 99.78K |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 651.63K | 489.29K | 660.84K | 2.38M | 2.8M | 2.74M | 4.38M | 4.04M |
| Total Debt | 0 | 0 | 108.5K | 204.95K | 52.89K | 234.47K | 243.66K | 93.95K |
| Net Debt | -445.16K | -1.23M | -19.12M | -51.32M | -37.15M | -21.7M | -7.27M | -8.3M |
| Debt / Equity | - | - | 0.01x | 0.00x | 0.00x | 0.01x | 0.01x | 0.01x |
| Debt / EBITDA | - | - | - | - | - | - | - | -0.00x |
| Net Debt / EBITDA | - | - | - | - | - | - | - | 0.42x |
| Interest Coverage | - | - | - | - | -70.63x | - | - | - |
| Total Equity | -201.8K▲ 0% | 943.28K▲ 567.4% | 19.7M▲ 1988.3% | 71.57M▲ 263.3% | 56.04M▼ 21.7% | 40.91M▼ 27.0% | 21.19M▼ 48.2% | 9.59M▲ 0% |
| Equity Growth % | - | 567.44% | 1988.32% | 263.33% | -21.7% | -27% | -48.21% | -224.77% |
| Book Value per Share | -0.03 | 0.15 | 3.17 | 6.56 | 5.16 | 3.77 | 1.97 | 0.88 |
| Total Shareholders' Equity | -201.8K | 943.28K | 19.7M | 71.57M | 56.04M | 40.91M | 21.19M | 9.59M |
| Common Stock | 11.37K | 11.37K | 622 | 1.11K | 1.09K | 1.07K | 1.08K | 1.1K |
| Retained Earnings | -4.32M | -6.75M | -12.66M | -25.02M | -39.28M | -55.24M | -76.03M | -89.07M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 0 | 0 | 0 | -92.69K | -371.39K | -107.46K | 153.99K | 40.33K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
LTRN Cash Flow Statement
Lantern Pharma Inc. (LTRN) cash flow — operating, investing & free cash flow history
| Line item | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -1.27M | -2.13M | -5.65M | -10.59M | -12.77M | -14.35M | -17.81M | -17.81M |
| Operating CF Margin % | - | - | - | - | - | - | - | - |
| Operating CF Growth % | - | -67.35% | -165.59% | -87.41% | -20.54% | -12.37% | -24.16% | -17.67% |
| Net Income | -1.73M | -2.43M | -5.91M | -12.36M | -14.26M | -15.96M | -20.78M | -18.92M |
| Depreciation & Amortization | -2.54K | 1.63K | 3.39K | 6.76K | 10.08K | 14.62K | 190.49K | 64.4K |
| Stock-Based Compensation | 185.6K | 117.76K | 1.19M | 961.54K | 1.19M | 1.07M | 0 | 737.56K |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | -76.32K | 0 | 0 | 203.22K | 906.49K | -5.17K | 549.36K | 154.29K |
| Working Capital Changes | 271.84K | 180.88K | -939.06K | 599.96K | -611.86K | 538.02K | 2.23M | 1.11M |
| Change in Receivables | 186.6K | 0 | 0 | 0 | 0 | 0 | -175.72K | 0 |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | 70.24K | 372.66K | 0 | 0 | 0 | 0 | 1.64M | 542.69K |
| Cash from Investing | 5.34K | -5.72K | -16.14K | -19.53M | 179.27K | -930.21K | 3.37M | 16.21M |
| Capital Expenditures | 0 | -5.72K | -16.14K | -15.5K | -27.84K | -18.73K | -12.6K | -4.8K |
| CapEx % of Revenue | - | - | - | - | - | - | - | - |
| Acquisitions | 5.34K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - |
| Other Investing | 5.34K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash from Financing | 535K | 2.92M | 23.66M | 63.42M | -2.18M | -500K | 66.71K | 971.78K |
| Debt Issued (Net) | 0 | 0 | 108.5K | 0 | 0 | 0 | 0 | 0 |
| Equity Issued (Net) | 0 | 1000K | 1000K | 1000K | -1000K | -500K | 66.71K | 971.78K |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | -2.48M | -500K | 0 | 0 |
| Other Financing | 535K | 0 | -28.94M | -4.64M | 2.78M | 0 | 0 | 0 |
| Net Change in Cash | -731.18K▲ 0% | 786.87K▲ 207.6% | 18M▲ 2187.2% | 33.3M▲ 85.0% | -14.78M▼ 144.4% | -15.81M▼ 6.9% | -14.43M▲ 8.7% | 286.67K▲ 0% |
| Free Cash Flow | -1.27M▲ 0% | -2.13M▼ 67.8% | -5.67M▼ 165.6% | -10.61M▼ 87.1% | -12.8M▼ 20.6% | -14.37M▼ 12.3% | -17.83M▼ 24.1% | -16.86M▲ 0% |
| FCF Margin % | - | - | - | - | - | - | - | - |
| FCF Growth % | - | -67.8% | -165.64% | -87.15% | -20.63% | -12.27% | -24.09% | 2.2% |
| FCF per Share | -0.20 | -0.34 | -0.91 | -0.97 | -1.18 | -1.32 | -1.66 | -1.66 |
| FCF Conversion (FCF/Net Income) | 0.74x | 0.88x | 0.96x | 0.86x | 0.90x | 0.90x | 0.86x | 0.89x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
LTRN Key Ratios
Lantern Pharma Inc. (LTRN) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM |
|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -654.95% | -57.24% | -27.09% | -22.35% | -32.93% | -66.93% | -125.98% |
| Return on Invested Capital (ROIC) | - | -3063.17% | -90.67% | -55.31% | -70.4% | -100.6% | -100.6% |
| Debt / Equity | - | 0.01x | 0.00x | 0.00x | 0.01x | 0.01x | 0.01x |
| Interest Coverage | - | - | - | -70.63x | - | - | - |
| FCF Conversion | 0.88x | 0.96x | 0.86x | 0.90x | 0.90x | 0.86x | 0.89x |
LTRN Frequently Asked Questions
Lantern Pharma Inc. (LTRN) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Lantern Pharma Inc. (LTRN) grew revenue by 0.0% over the past year. Growth has been modest.
Lantern Pharma Inc. (LTRN) reported a net loss of $18.9M for fiscal year 2024.
Dividend & Returns
Lantern Pharma Inc. (LTRN) has a return on equity (ROE) of -66.9%. Negative ROE indicates the company is unprofitable.
Lantern Pharma Inc. (LTRN) had negative free cash flow of $16.9M in fiscal year 2024, likely due to heavy capital investments.
Explore More LTRN
Lantern Pharma Inc. (LTRN) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates